Mylan Lab’s Proposed Merger with King Pharmaceutical (Abridged) Harvard Case Solution & Analysis

Mylan Lab's Proposed Merger with King Pharmaceutical (Abridged) Case Solution

Synergy Valuation

As stated in the case; the merger will allow Mylan to reduce its costs by $100 million, mainly in the form of selling costs. This reduction in cost can be evaluated by calculating the perpetuity value for after-tax synergies as reduction in costs tend to increase the tax payment.The synergies valuation is conducted using after tax synergy value. The total value fir synergies equals to $435.16 million. (See Exhibit 2)

Evaluation of the Deal

The value created by the deal could be evaluated by determining the value per share, which is the actual wealth of the shareholders’,after taking into consideration the results after the acquisition. The operating income after the acquisitions, equals to the sum of the operating incomes of King and Mylan, along with the cost savings by synergies of $100 million. All the other measures are calculated by simply adding the values for the two firms. On the basis of these calculations; the value per share for Mylan, after the acquisition, equals to $10.2, which is a significant improvement in the value per share, i.e. form -$0.67 to $10.2.

Total value of the deal, including the synergies, equals to $535.16 million with an investment of $4000 million, creating 13% rate of return.

This implies that the merger tends to create high value for the shareholders of Mylan Inc., with 13% rate of return.

Recommendations

Although, the conduct of Perry Capital is unethical, but from the above analysis, as the merger would create value for all the shareholders of Mylan Inc., therefore, the investors should vote in the favor of the merger deal. However, the conducted analysis is based on certain assumptions and a limited date, so the investors are also recommended to financially evaluate the opportunity by taking the free cash flows of both of the firms under consideration.

Exhibits

Exhibit 1: DCF Valuation

Valuation
  King Mylan K+M
Tax Rate 40% 35% 35%
Discount Rate (Assumed) 15% 15% 15%
Growth Rate (Assumed) 3% 3% 3%
       
Free Cash Flow      
EBIT 474.8 460 560
NOPAT 283.9149 300.2653 365.5404
Add: Depreciation 124.6 0 124.6
Less: Change in Capex 447.8 139.9 587.7
Change in NWC (614.2) 181.6 (432.6)
Free Cash Flow 574.9 (21.2) 335.0
Enterprise Value (Perpetuity) 4934.686 -182.264 2875.763
Less: LTD -345 0 -345
Equity Value 4589.686 -182.264 2530.763
Shares Outstanding 271.8 268.6 508.7105
Value Per Share 16.88626 -0.67857 4.97486
Price Offered Per Share 16.659  
Total Asked Price 4000  
Shares Purchased 240.1105  
Total value for shares purchased 4054.568  
Investment 4000  
Premium on shares 1.013642  
Synergies Value 435.1671  
Total Deal Value 535.1671  
Rate of Return 13%    

Exhibit 2: Synergy Valuation

Cost Synergies Valuation
Synergies 100
After Tax Synergies 65.27507
Synergies Value 435.1671

.......................

This is just a sample partial case solution. Please place the order on the website to order your own originally done case solution.

Share This

SALE SALE

Save Up To

30%

IN ONLINE CASE STUDY

FOR FREE CASES AND PROJECTS INCLUDING EXCITING DEALS PLEASE REGISTER YOURSELF !!

Register now and save up to 30%.